Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 18/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9731788 | 0.94 | MAPT (0.34) | MAPTCRBNDDB1 | |
| SCHEMBL1137425 | 0.82 | MAPT (0.36) | MAPTCRBN | |
| SCHEMBL9055828 | 0.72 | CRBN (0.37) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29640501 | 0.72 | MAPT (0.38) | MAPT | |
| SCHEMBL11738873 | 0.71 | MAPT (0.36) | MAPT | |
| SCHEMBL7098448 | 0.70 | CRBN (0.36) | CRBNDDB1 | |
| SCHEMBL15547045 | 0.69 | — | — | |
| SCHEMBL10620948 | 0.69 | CRBN (0.42) | CRBNDDB1 | |
| SCHEMBL5946816 | 0.69 | DDB1 (0.32) | CRBNDDB1 | |
| SCHEMBL5635896 | 0.69 | SRD5A1 (0.33) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324695-A | Method for selectively preparing quinoline-2-ketone or 3, 4-dihydro-quinoline-2-ketone compound under regulation of photocatalyst | 浙江工业大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-117820289-A | Cyclic sulfone compound, salt, preparation method and application thereof | 中国人民解放军海军第九七一医院 | 2024-04-05 | — | — | CN | disclosed |
| US-7417032-B2 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-26 | — | — | US | disclosed |
| US-20070054912-A1 | Modulators of acetylcholine receptors | ASTLES PETER C | 2007-03-08 | — | — | US | disclosed |
| US-7148236-B2 | Modulators of acetylcholine receptors | MERCK & CO., INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060035841-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| US-20060025349-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
| US-20050182088-A1 | Modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-08-18 | — | — | US | disclosed |
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
| US-5622961-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5578724-A | INHIBITORS OF 5-ALPHA-REDUCTASE | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996035422-A1 | METHODS FOR INHIBITING BONE LOSS | ELI LILLY AND COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1996009046-A1 | 5α-REDUCTASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0703221-A1 | 5 alpha-reductase Inhibitors | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1995021824-A1 | 6-ARYL-(METHYL- OR METHYLIDENE)-QUINOL-2-ONE DERIVATIVES AS VOLTAGE GATED POTASSIUM CHANNEL BLOCKERS | JOHN WYETH & BROTHER LTD (GB) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021825-A1 | 6-ARYL-(METHYL- OR METHYLIDONE)-QUINOLINE DERIVATIVES AS VOLTAGE-GATED POTASSIUM CHANNEL BLOCKERS | JOHN WYETH & BROTHER LTD. (GB) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | MAPT 4012/4885CRBN 4264/4885DDB1 452/4885 |
| US-20050182088-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | MAPT 826/4885CRBN 1869/4885DDB1 2381/4885 |
| US-20060035841-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | MAPT 2337/4885CRBN 4172/4885DDB1 2445/4885 |
| US-20060025349-A1 | D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | MAPT 2411/4885CRBN 4303/4885DDB1 3279/4885 |
| US-20070054912-A1 | Modulators of acetylcholine receptors | CHRM3, CHRNG, CHRM5 | MAPT 3360/4885CRBN 1227/4885DDB1 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.